Results 1 to 10 of about 386 (85)

Novel oxazolidinones harbor potent in vitro activity against the clinical isolates of multidrug-resistant Mycobacterium tuberculosis in China [PDF]

Frontiers in Medicine, 2022
ObjectiveTo investigate the in vitro activities of five oxazolidinones in parallel against the reference strains of different mycobacterial species and clinical isolates of Mycobacterium tuberculosis (Mtb), and shed light on the differences in the ...
Chenqian Wang, Chenqian Wang, Guirong Wang, Fengmin Huo, Yi Xue, Junnan Jia, Lingling Dong, Liping Zhao, Fen Wang, Hairong Huang, Hongfei Duan   +10 more
doaj   +2 more sources

New Oxazolidinones for Tuberculosis: Are Novel Treatments on the Horizon? [PDF]

Pharmaceutics
Multidrug-resistant tuberculosis (MDR-TB) is a global health concern. Standard treatment involves the use of linezolid, a repurposed oxazolidinone. It is associated with severe adverse effects, including myelosuppression and mitochondrial toxicity.
Ricky Hao Chen, Andrew Burke, Jin-Gun Cho, Jan-Willem Alffenaar, Lina Davies Forsman   +4 more
doaj   +2 more sources

panTB-HM: a multi-arm clinical trial of a pan-TB regimen targeting both host and microbe [PDF]

Trials
Background Newer oxazolidinones will be required to advance regimens in pan-TB indications. The addition of host-directed agents may help promote the recovery of lung function during TB treatment and prevent post-TB lung disease.
D. Mudzengi, S. Mashatole, Q. Xiang, C. Adrion, N. Glover, T. Ngwanto, J. Mdluli, S. Boniface, M. Rassool, B. Matome, L. Paramo, E. Svensson, A. Fasanmi, S. Angelo, M. Moyo, C. Marx, C. Khosa, L. Mokaba, N. Mofokeng, J. Lalashowi, C. Nacy, S. Charalambous, E. Fumane, V. Maphossa, T. Beattie, W. Brumskine, C. Venter, D. Mapamba, N. Heinrich, S. Rajaram, S. Kooverjee, L. Botha, M. Nell, A. Easton, S. Foraida, Robin Mark Warren, Issa Sabi, N. Ntinginya, R. S. Wallis, panTB-HM Consortium   +39 more
doaj   +2 more sources

Assessment of Lipophilicity Parameters of Antimicrobial and Immunosuppressive Compounds [PDF]

Molecules, 2023
Lipophilicity in addition to the solubility, acid-base character and stability is one of the most important physicochemical parameters of a compound required to assess the ADMET properties (absorption, distribution, metabolism, excretion and toxicity) of
Dawid Wardecki, Małgorzata Dołowy, Katarzyna Bober-Majnusz   +2 more
doaj   +2 more sources

Mycobactericidal Activity of Sutezolid (PNU-100480) in Sputum (EBA) and Blood (WBA) of Patients with Pulmonary Tuberculosis [PDF]

PLoS ONE, 2014
Sutezolid (PNU-100480) is a linezolid analog with superior bactericidal activity against Mycobacterium tuberculosis in the hollow fiber, whole blood and mouse models.
Robert S Wallis, Andreas H Diacon, Sven O Friedrich   +2 more
exaly   +2 more sources

Comparison of the in vitro activity of linezolid, tedizolid, sutezolid, and delpazolid against rapidly growing mycobacteria isolated in Beijing, China

International Journal of Infectious Diseases, 2021
Background: The natural resistance of rapidly growing mycobacteria (RGM) to multiple antibiotics renders the treatment of the infections caused less successful.
Xia Yu, Xiaopan Gao, Hairong Huang
exaly   +3 more sources

Current Status and Perspectives of Antibacterial Agents Belonging to 2-Oxazolidinones [PDF]

Pharmaceuticals
In the last three decades, 2-oxazolidinones have emerged as an important class of inhibitors of bacterial protein synthesis, effective in the treatment of multidrug-resistant (MDR) bacterial infections. From a public health perspective, the importance of
Jessica Ceramella, Annaluisa Mariconda, Domenico Iacopetta, Maria Marra, Alessia Catalano, Paola Checconi, Stefano Aquaro, Carmela Saturnino, Pasquale Longo, Maria Stefania Sinicropi   +9 more
doaj   +2 more sources

Genomic-based genotype and drug susceptibility profile of Mycobacterium kansasii in China [PDF]

Frontiers in Microbiology
To analyze subtypes, microbiological characteristics and antimicrobial susceptibility of Mycobacterium kansasii in China, a total of 153 M. kansasii isolates, collected from national drug resistance surveillance, were genotyped with whole genome ...
Yiting Wang, Yiting Wang, Xichao Ou, Bing Zhao, Hui Xia, Yang Zheng, Yang Zhou, Ruida Xing, Yuanyuan Song, Shengfen Wang, Yanlin Zhao, Huiwen Zheng   +11 more
doaj   +2 more sources

Host-Pathogen Dual Targeting With Repurposed Drugs Identifies a Synergistic Therapy for Intracellular Staphylococcus aureus. [PDF]

Microbiologyopen
A large intracellular drug‐repurposing screen identifies a potent synergy between 5‐fluoro‐2′‐deoxycytidine and rifapentine, acting through dual host–pathogen targeting to reduce Staphylococcus aureus burdens across strains, cell types, and infection models (created with BioRender).
Lorente-Torres B, Ferrero HÁ, Castañera P, Llano-Verdeja J, Fernández-Martínez S, Herrero-González A, Javadimarand F, López R, Aparicio JF, Edwards AM, Behrends V, Mateos LM, Mourenza Á, Letek M.   +13 more
europepmc   +2 more sources

Targeting the Heart of Mycobacterium: Advances in Anti-Tubercular Agents Disrupting Cell Wall Biosynthesis [PDF]

Pharmaceuticals
Mycobacterium tuberculosis infections continue to pose a significant global health challenge, particularly due to the rise of multidrug-resistant strains, random mycobacterial mutations, and the complications associated with short-term antibiotic ...
Ahmad Diab, Henry Dickerson, Othman Al Musaimi   +2 more
doaj   +2 more sources